Identifies a noninvasive, objective biomarker (reduced saccade velocity) that could improve screening, stratification, and monitoring of depressive symptoms in PD—useful for clinical care and trial design—though it does not directly reveal therapeutic targets.

Offers a noninvasive discourse-level behavioral biomarker for early/subclinical PD detection and patient stratification that could inform clinical assessments and outcome measures in trials, though it does not provide molecular mechanisms or direct therapeutic targets.

Findings support subtype-specific DBS programming to improve clinical efficacy and energy efficiency (battery life and device management), but the study offers limited direct insight for pharmacological target discovery or neuroprotective strategies.

Points to Cav1.2 (CACNA1C) haploinsufficiency as a possible, clinically actionable contributor to movement disorders—supporting genetic testing and DBS consideration—but single-case data limit immediate translational impact for Parkinson's-targeted therapies.

While not mechanistic, the study provides robust, less-biased prognostic data and genetic predictors (GBA, APOE e4) that are valuable for clinical trial design, patient stratification/enrichment, and prioritizing subgroups for targeted therapeutic strategies.

Indicates wearable-derived dyskinesia burden may serve as a pragmatic digital biomarker to monitor and potentially guide PD treatment, offering translational clinical utility if confirmed in larger prospective studies.

Offers a noninvasive, ATP-focused salivary biomarker assay reflecting metabolic/mitochondrial perturbations relevant to PD that could support patient stratification or monitoring, but it has limited immediate therapeutic discovery impact and requires larger clinical validation.

Establishes a blood-based prognostic biomarker useful for early-stage MSA patient stratification in clinical trials and outcome prediction—valuable for translational and trial design but offering limited direct therapeutic targets for Parkinson's drug discovery.

This provides a prospective biomarker for early identification of depression risk in prodromal PD and implicates oxidative‑stress/urate pathways as mechanistically relevant and potentially targetable, though causality and therapeutic utility remain unproven and sample size is limited.

The negative primary outcome limits immediate therapeutic relevance, but the modest cognitive signal and gut–brain axis approach justify larger, mechanistically focused trials to assess microbiome‑based strategies for cognitive symptoms in PD.

AST/ALT is an inexpensive, routinely available serum marker that could aid PD subtyping and trial stratification, offering translational potential despite limited mechanistic insight and the need for prospective validation.

While it contains no mechanistic or therapeutic findings, improving patient literacy and engagement around DMTs can boost recruitment, informed consent, and trial readiness—indirectly accelerating Parkinson’s therapeutic development.

Supports expanding a noninvasive, symptomatic treatment option to carefully selected very elderly patients with tremor-predominant Parkinson's disease, increasing clinical applicability though it offers no disease-modifying insights.

Identifies a non-invasive biomarker candidate that could aid diagnosis or stratification, though small sample sizes and no functional validation limit immediate therapeutic or mechanistic utility.

This links an RNA/toxic-gain-of-function mechanism and a genetic biomarker to parkinsonian manifestations in a defined subpopulation, which could help stratify patients or suggest mechanistic parallels for targeted research, but it offers limited immediate translational value for typical…

Identifies a noninvasive EEG biomarker that could help detect and track cognitive decline and stratify patients in clinical studies, offering translational utility for outcome measurement though it does not directly inform molecular therapeutic targets.

Zonal corneal epithelial thickness mapping is a non-invasive biomarker candidate that could help disease staging and patient stratification in trials, but it offers limited direct mechanistic or therapeutic insight for Parkinson's drug discovery.

Offers mechanistic cellular evidence that SNCA overexpression drives mitochondrial/oxidative-stress–linked, caspase-mediated cell death—insightful for understanding alpha-synuclein toxicity relevant to Parkinson's disease biology but of limited direct translational value because the work is in…

Provides a promising noninvasive wearable method for early PD detection and individualized gait rehabilitation that could aid monitoring and trial stratification, but it offers little mechanistic or therapeutic-target insight for drug discovery.

Although it does not advance disease mechanisms or therapies directly, subtype-aware augmentation tackles data scarcity and class imbalance to enable more reliable, personalized FOG phenotyping and monitoring, which can improve outcome measurement and model-based endpoints in clinical studies and…